Day: August 20, 2025

Product sales from Olverembatinib in the first half of 2025 increased 93% year-over-year to US$30.3 million (RMB217.4 million), primarily attributable to the expansion of NRDL coverage Commenced commercial sales of Lisaftoclax in China, following approval on July 10, 2025 by China’s NMPA for the treatment of adult patients with CLL/SLL who have previously received at least one systemic therapy including BTK inhibitors Registrational Phase III trial for 1L HR MDS (GLORA-4) cleared by FDA and EMA, and first patients enrolled in Europe and China Completed a top-up placement in July 2025, resulting in US$190.1 million in net proceeds Nine registrational clinical trials are in progress, including three cleared by FDA Chinese (Mandarin) language investor webcast at 9:00 pm EDT on August 20, 2025 / 9:00 am HKT on August 21, 2025, and English...

Revenue of $10,587,075 in Q2 2025, up 49% year-over-year; gross margin of 32% Adjusted EBITDA loss of $276,259, an 85% year-over-year improvement Current cash balance strengthened to approximately $20M Operational highlights included clearances and demonstrations with defense and energy clients and new commercial wins in forestry and agriculture. Subsequent events included additional NATO-aligned contracts and growth capitalTORONTO, Aug. 20, 2025 (GLOBE NEWSWIRE) — Volatus Aerospace Inc. (TSXV:FLT) (OTCQB:TAKOF) (Frankfurt:A3DP5Y/ABB.F) (“Volatus” or “the Company”), a leader in aerial solutions, is pleased to announce its financial results for the three and six months ended June 30, 2025 (Q2 2025). All dollar figures are stated in Canadian dollars, unless otherwise indicated. Q2 2025 delivered another...

CALGARY, Alberta, Aug. 20, 2025 (GLOBE NEWSWIRE) — Inventronics Limited (the “Corporation”) (IVX:TSX Venture), a designer and manufacturer of enclosures for the telecommunications, cable, electric distribution, energy, and other industries in Canada and the USA, today announced its unaudited 2025 Q2 financial results. For the three months ended June 30, 2025, Inventronics reported net earnings of $138,000, or 2.8 cents per share, on revenue of $2,190,000 compared to net earnings of $141,000, or 2.9 cents per share, on revenue of $1,950,000 for the three months ended June 30, 2024. For the six months ended June 30, 2025, Inventronics reported net earnings of $321,000, or 6.6 cents per share, on revenue of $4,617,000 compared to net earnings of $149,000, or 3.1 cents per share, on revenue of $3,394,000 for the comparative period...